TAE Life Sciences raises $40m for neutron beam cancer treatment

March 13, 2018 By Fink Densford

TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.

The newly launched Foothill Ranch, Calif.-based company, which operates as a subsidiary of fusion energy company TAE Technologies, is developing neutron beam technology intended for Boron Neutron Capture Therapy.

As part of the company’s launch, it announced that it is partnering with Chinese BNCT company Neuboron Medtech, and that its first neutron beam system will be delivered to Neuboron for its first medical use.

“I am pleased to be publicly launching TAE Life Sciences, and for the opportunity to provide solutions for aggressive and late-stage cancer with promising new applications of accelerator-based neutron beam technology. BNCT has been investigated as a promising area of treatment for some time, but challenged by the limited radiation options for convenient clinical practice. Now, TAE Life Sciences stands ready to offer a compelling and compassionate application of medical science innovation, increasing accessibility to treatment options for a challenging disease, and improving outcomes for patients around the world,” TAE Life Sciences CEO Bruce Bauer said in a press release.

BNCT is designed to treat multi-centric, sometimes inoperable tumors diffusely embedded in normal tissue intended to provide minimal harm to healthy cells. TAE Life Science’s proprietary BNCT platform includes a tunable neutron beam and compact form factor, the company said.

Funding in the round was led by Artis Ventures, and TAE Life Sciences said it plans to work with clinical research partners to investigate the use of accelerator-based BNCT to hasten development of its proprietary beam systems as it pursues regulatory clearance.

“TAE Life Sciences has a differentiated platform in the world of nuclear medicine and oncology, and is backed by strong, early results. Their seasoned team has already shown they can execute in a short period of time while continuing to garner interest from across the globe. As early lead investors, we look forward to helping TAE Life Sciences in a similar capacity as our work with Stemcentrx. Both companies have striking similarities in their potential to reshape the future of oncology,” Artis Ventures co-founder and prez Stuart Peterson said in a prepared statement.

FDA just made pooled COVID testing easier
COVID-19 molecular tests have already been authorized for individual use will have an easier time getting an FDA nod for pooled testing. The FDA said today it will add tests by manufacturers who validated their nasal specimen test for pooling to its list of tests available for use with pooled nasal specimens. This could expand… […]
FDA clears Spinal Elements 3D additive manufactured interbody devices
Spinal Elements today said it received FDA 510(k) clearance for its Lucent 3D line of 3D-printed interbody devices. The Lucent 3D implant has a strut-and-lattice structure with a bone graft chamber access lid that is designed for a surgeon to deliver large amounts of tightly packed graft inside the interbody structure. The lid design helps… […]
Medtronic blood pump recall is serious
Medtronic is recalling a blood pump that can stop during cardiopulmonary bypass surgery due to electrical failure. The Bio-Console 560 extracorporeal blood pumping console is used to pump and return blood to a person during bypass, a procedure that temporarily takes over the function of the heart and lungs. The cardiopulmonary bypass procedure provides both… […]
In situ cure technology molds next-gen medical implants
Innovation in silicone technology has moved beyond defining specific material characteristics and into offering implantable devices that cure and form into shape inside the human body. Benny David, NuSil from Avantor Medical device manufacturers have long relied on highly purified silicone elastomers to fabricate components or entire devices for implantation. Now, recent innovations offer manufacturers… […]
How to prevent and troubleshoot short shots in medtech molding
Deliberate processes to identify and remediate the problem can yield high-quality products and keep patients safe. Shane Vandekerkhof, RJG Short shots are among the most common and visually obvious quality issues most molders face, but they can cause fatal flaws in medical devices. Imagine if a luer lock connector was short. You run the risk… […]
AdvaMed launches medtech podcast
AdvaMed today announced the launch of a new podcast, MedTech POV. AdvaMed president and CEO Scott Whitaker hosts the podcast, which covers the intersection of medtech and policy from a variety of perspectives. Each episode will feature discussions with medtech and healthcare policy leaders on issues that are driving the day — from business to… […]
This wearable could signal cytokine storms
Researchers at the University of Texas at Dallas have developed a sweat sensor that could detect cytokine storms in patients suspected of having COVID-19 and other illnesses. Early on in the pandemic, doctors found that patients who developed a surge of pro-inflammatory immune proteins, called “cytokine storms,” were more often the sickest and at the… […]
How to evaluate laser performance for medical device manufacturing
Laser processing provides automation and efficiencies that help meet FDA regulations and produce superior medical device components. David Locke, ACSYS Lasertechnik US Laser systems have become essential to the production of better-designed medical devices. The precision, repeatability and scale needed to manufacture next-generation medical products rely heavily on the advantages that lasers bring to contract… […]
EPA delayed notifying residents of ethylene oxide emissions
The EPA delayed notifying neighbors of an Illinois medical device sterilization plant of ethylene oxide (EtO) emissions the agency measured in 2018, according to an inspector general’s report released yesterday. The report also says that “leadership” in the agency’s Office of Air and Radiation also failed to conduct public meetings with residents either near the… […]
9 medical devices you should keep an eye out for in 2021
The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021. Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek… […]
Greenlight Guru to provide QMS to NIH diagnostics program
NIH has chosen Greenlight Guru to provide quality management software for its COVID-19 rapid diagnostics program. The agency launched the Rapid Acceleration of Diagnostics (RADx) program in March 2020 to speed the development, commercialization and implementation COVID-19 testing technologies. As the only QMS provider currently available to all projects in the RADx program, Greenlight Guru… […]